The Journal of Infectious Diseases · 2006 · 111 citations · 17 references
Life SciencesImmunologyMicrobiologyAntibody EngineeringHost-pathogen InteractionsMicrobial PathogenesisAntifungal AgentsAntifungal TherapyFungal ImmunologyFungal InfectionsFungal PathogenesisMucosal Barrier FunctionAntibodiesBispecific Antibody FragmentsCandida Albicans InfectionCandida-host InteractionsExpression LibrariesFluconazole TherapyVaginal CandidiasisVariable Heavy Domain Antibodies
Antibody variable domains (domain antibodies [DAbs]) are genetically engineered antibody fragments that include individual heavy-chain (VH) or kappa-chain (Vkappa) variable domains and lack the Fc region. Human DAbs against the 65-kDa mannoprotein (MP65) or the secretory aspartyl proteinase (SAP)-2 of Candida albicans (monospecific DAbs) or against both fungal antigens (heterodimeric, bispecific DAbs) were generated from phage expression libraries. Both monospecific and bispecific DAbs inhibited fungus adherence to the epithelial cells of rat vagina and accelerated the clearance of vaginal infection with the fungus. When heterodimeric DAbs were used, the clearance of infection was at least equivalent to treatment with fluconazole. The in vivo protective effects of DAbs were demonstrated by both pre- and postchallenge schedules of DAb administration and with both fluconazole-susceptible and fluconazole-resistant strains of C. albicans. This is the first demonstration that human DAbs lacking the Fc constituent can efficiently control an infection and can act largely by inhibiting adherence.
17
Phage antibodies: filamentous phage displaying antibody variable domains
John McCafferty, Andrew D. Griffiths, Greg Winter et al. · Nature · 1990 · 2.4K citations
Martin Schaller, Matthias Bein, Hans Christian Körting et al. · Infection and Immunity · 2003 · 178 citations · Full text
Flavia De Bernardis, Silvia Arancia, Luisella Morelli et al. · The Journal of Infectious Diseases · 1999 · 169 citations · Full text